Telix Reports First US Patients Dosed with FDA-Approved Pixclara for Glioma Imaging

Shots: Telix Pharmaceuticals reported that the first pts. in the US have been dosed with Pixclara (floretyrosine F-18), marking the start of commercial availability of the FDA-approved PET imaging drug for glioma Pixclara (IV) is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related changes in adults and pediatric patients one month of age and older, in conjunction with other diagnostic evaluations The first commercial doses were administered in Indianapolis, Indiana, and Cleveland, Ohio, with PharmaLogic Holdings supplying finished unit doses to the US market; Pixclara is also being evaluated in a P-III study for potential expansion into brain metastases imaging Ref: Telix | Image: Telix | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com The post Telix Reports First US Patients Dosed with FDA-Approved Pixclara for Glioma Imaging appeared first on PharmaShots.